Patients Bear Increased Financial Burden for Growth Hormone Treatment Despite FDA Approval and Lower Total Cost
(World News Science)

Despite an FDA approval of growth hormone treatment for children with idiopathic short stature (ISS), the mean cost burden to patients and their families has increased over time, according to findings from researchers at Children`s Hospital of Philadelphia (CHOP) and the Leonard Davis Institute of Health Economics (LDI) of the University of Pennsylvania. The findings were presented during ENDO 2019 in New Orleans, LA. Study findings indicate that increased patient cost-sharing and coverage restrictions are responsible for a greater cost burden that...